GREENVILLE, N.C. — Mayne Pharma launched Butalbital acetaminophen (APAP) tablets, 50mg/300mg in the United States. Butalbital/APAP is indicated for the treatment of tension headache (migraine).
Mayne Pharma will distribute the drug on behalf of its partner, Mikart, which developed the product and also is manufacturing the product.
“We are very pleased to have licensed this product from Mikart, one of our strategic partners,” said Mayne Pharma CEO Scott Richards. “This will be the first generic alternative to BUPAP and will bring patients and payers improved medication affordability.”
Mayne Pharma directly markets more than 50 products and has a growing pipeline of more than 40 generic and branded drug products targeting U.S. markets with IMS sales greater than $6 billion.